Phuturdex › Diseases › Hematologic neoplasm
Drugs in development · updated 30 October 2026
Hematologic neoplasm: drugs in development
As of 30 October 2026 there are 184 active clinical trials (recruiting or ongoing, phases I–III) on 216 drugs for hematologic neoplasm. 82 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 82 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 30 | NCT03818334 |
| VenetoclaxVentoclax, Venclexta® | III | 10 | NCT07007312 |
| AzacitidineAzacytidine, 5-azacytidine | III | 8 | NCT07007312 |
| CytarabineAra-C, Cytosine Arabinoside | III | 5 | NCT07007312 |
| DabrafenibTafinlar®, Finlee® | II–III | 5 | NCT07440290 |
| PertuzumabPerjeta, Poherdy® | II–III | 4 | NCT05722886 |
| TrametinibMekinist®, Spexotras® | II–III | 4 | NCT07440290 |
| TrastuzumabHerceptin, tratuzumab | II–III | 4 | NCT05722886 |
| ZiftomenibKomzifti® | III | 4 | NCT07007312 |
| AlectinibAlecensa® | II–III | 3 | NCT05722886 |
| AtezolizumabTecentriq, MPDL3280A | II–III | 3 | NCT05722886 |
| BortezomibVelcade, Bortezomib Hospira® | III | 3 | NCT07635511 |
| CobimetinibCotellic® | II–III | 3 | NCT05722886 |
| EntrectinibRozlytrek® | II–III | 3 | NCT05722886 |
| LetermovirPrevymis® | III | 3 | NCT05711667 |
Sorted by most advanced phase and number of active trials. Showing 15 of 134 drugs.
All 216 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Polycythemia vera 49 drugs
- Myelofibrosis 91 drugs
- Thrombocythemia, Essential 43 drugs
- Myeloproliferative disorders 91 drugs
- Acute myeloid leukemia 314 drugs
- Blastic plasmacytoid dendritic cell neoplasm 24 drugs
- Myelodysplastic Syndromes 203 drugs
- Chronic myelomonocytic leukemia 90 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- Acute biphenotypic leukaemia 80 drugs
- Atypical chronic myeloid leukemia 22 drugs
- Myelodysplastic–myeloproliferative diseases 40 drugs
Broader categories
- Hematologic Diseases 57 drugs
- Neoplasm 671 drugs
- Immune System Diseases 54 drugs
- Immunoproliferative disorder 16 drugs
- Lymphatic system disease 20 drugs
- Lymphoproliferative disorders 51 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Phuturdex; NLM MeSH term: D019337 “Hematologic Neoplasms”.